Ongoing studies of this combination include a phase III trial of sorafenib plus bortezomib in younger adults (up to age 29) with newly diagnosed FLT3-ITD AML (NCT01371981) and sorafenib plus bortezomib followed by decitabine in newly diagnosed or R/R AML regardless of FLT3 status (NCT01861314). The gene discussed is FLT3; the disease is acute myeloid leukemia.